Compare XBIT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | RNXT |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.8M | 79.4M |
| IPO Year | 2015 | 2021 |
| Metric | XBIT | RNXT |
|---|---|---|
| Price | $1.88 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.13 |
| AVG Volume (30 Days) | 92.8K | ★ 360.8K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | $30.47 | $195.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.80 | $0.70 |
| 52 Week High | $3.44 | $2.59 |
| Indicator | XBIT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 36.64 |
| Support Level | $1.80 | $1.09 |
| Resistance Level | $2.42 | $1.30 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 27.27 | 36.72 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.